This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
Columbia University Medical Center is recruiting individuals ages 18-65 who are seeking treatment for opioid use disorder to participate in a research treatment study. For your participation, you'll receive treatment with buprenorphine (either sublingual or injectable) at no cost. Participants will complete an overnight inpatient stay to start…
Have an Opioid Use Disorder? We need your help for an inpatient clinical research study! Help the New York State Psychiatric Institute research better treatment options for those with opioid use disorder.You could earn up to $12,017.00.You must meet the following criteria: - Age 18 -59 years old- Have opioid use disorder- Be currently taking an oral daily…
This research study uses MRI scans to compare the effect of two medications on suicidal thoughts and brain activity in people who have opioid use disorder. We hope to develop a better understanding of how well these two medications help depression and suicidal thoughts. You may qualify if you have opioid use disorder and suicidal thoughts. Participation…
Early Age-Related Hearing Loss Investigation (EARHLI) is a study to obtain information on how a hearing aid-based intervention can prevent cognitive decline in those at risk for Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). Age-related hearing loss (ARHL) is the third most common chronic condition in older adults. The…
This is a 22-week treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 2 study to evaluate the efficacy, safety, and tolerability of the study drug E2027, in participants with Dementia with Lewy Bodies (DLB) Lewy Body Dementia - LBD. The main purpose of this research study is to find if a new drug called E2027 works in people who…
This study is of a drug called CT1812, that is being evaluated as a possible treatment for Dementia with Lewy Bodies. In this study, which is carried out at multiple sites in the country, participants receive either CT1812 at one of two doses or placebo. The duration of the study is up to about 35 weeks. Participants receive blood tests, cerebrospinal fluid…
A significant focus of healthcare research is aimed at biomarker discoveries in brain and heart diseases in particular, and their impact on the human body in general. MRI is a key component in these healthcare services. It provides a non-invasive and non-ionizing approach to diagnose pathologies along with significant internal and external contrast…